Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EPS (Basic) (2023 - 2025)

Compass Therapeutics' EPS (Basic) history spans 3 years, with the latest figure at -$0.08 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 27.27% year-over-year to -$0.08; the TTM value through Dec 2025 reached -$0.42, down 16.67%, while the annual FY2025 figure was -$0.42, 16.67% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.08 at Compass Therapeutics, roughly flat from -$0.08 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.06 in Q1 2023 and bottomed at -$0.14 in Q2 2025.
  • The 3-year median for EPS (Basic) is -$0.08 (2023), against an average of -$0.09.
  • The largest YoY upside for EPS (Basic) was 27.27% in 2025 against a maximum downside of 55.56% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at -$0.1 in 2023, then fell by 10.0% to -$0.11 in 2024, then increased by 27.27% to -$0.08 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's EPS (Basic) are -$0.08 (Q4 2025), -$0.08 (Q3 2025), and -$0.14 (Q2 2025).